## LLY: Eli Lilly and Company - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -6.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.0% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($941.45)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Guggenheim Maintains Buy on Eli Lilly (LLY) After "Another Impressive Year"**
- Source: Finviz | 20251208T123600 | Bullish | Relevance: 99%
- Guggenheim has reiterated its "Buy" rating on Eli Lilly (NYSE: LLY) and increased its price target to $1,163, citing the company's "impressive year" in 2025 driven by strong execution and its leadership in the weight loss drug market. Eli Lilly's exceptional financial performance, particularly its Mounjaro and Zepbound drugs, and the promising results of its potential weight loss pill, orforglipron, underscore the firm's confidence in the company's continued growth. The company reported $17.6 billion in Q3 2025 revenue, a 53.8% increase year-over-year, significantly beating analyst estimates.

**2. Eli Lilly and Company $LLY Stake Cut by Vega Investment Solutions**
- Source: MarketBeat | 20251208T130841 | Somewhat-Bullish | Relevance: 99%
-  Vega Investment Solutions reduced its stake in Eli Lilly and Company by 0.9%, selling 1,042 shares, though LLY remains its second-largest holding, valued at $86.95 million. Eli Lilly surpassed Q3 earnings expectations with an EPS of $7.02 and revenue of $17.6 billion, and analysts maintain a "Moderate Buy" rating with an average price target of $1,087.32. The company also announced a quarterly dividend of $1.50 per share.

**3. Lilly’s GLP-1 Surge Dwarfs Abbott’s Steady Device Growth With 54% Revenue Jump**
- Source: 24/7 Wall St. | 20251208T133249 | Bullish | Relevance: 99%
-  Eli Lilly (LLY) reported an explosive 54% revenue growth, driven primarily by its GLP-1 drugs Mounjaro and Zepbound, and raised its full-year guidance. In contrast, Abbott Laboratories (ABT) showed steady 6.9% revenue growth, propelled by its medical device segment. This highlights a strategic divergence between Lilly's concentrated bet on incretin therapies and Abbott's diversified portfolio, leading to different risk profiles and market valuations.

**4. Eli Lilly's Stock Drops as It Slashes the Price of Zepbound: Time to Buy the Dip?**
- Source: Finviz | 20251206T172700 | Somewhat-Bullish | Relevance: 98%
- Eli Lilly's stock dropped after announcing a price cut for its popular weight loss drug, Zepbound. This strategic move aims to expand access and counter competition, despite concerns about its impact on growth. The company's robust pipeline, strong financial results, and advancements in other therapeutic areas still make it an attractive investment.

**5. Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025**
- Source: Oncodaily | 20251209T110858 | Bullish | Relevance: 98%
-  Eli Lilly and Company announced the reappointment of Dr. Carolyn R. Bertozzi to its Board of Directors, effective December 8, 2025. Dr. Bertozzi, a Nobel laureate, will serve on the Science and Technology Committee and the Ethics and Compliance Committee, reinforcing Lilly's commitment to scientific excellence and ethical leadership. Her return is expected to significantly contribute to the company's therapeutic innovations, particularly in oncology and immunology.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-04 | BMO Capital | $1200 | $1100 | +9% |
| 2025-11-24 | Morgan Stanley | $1290 | $1171 | +10% |
| 2025-11-24 | Bernstein | $1300 | $1100 | +18% |
| 2025-11-19 | Truist Securiti | $1182 | $1038 | +14% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-04 | BMO Capital | main | Outperform |
| 2025-11-24 | Morgan Stanley | main | Overweight |
| 2025-11-24 | Bernstein | main | Outperform |
| 2025-11-19 | Truist Securiti | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 20 ($2.11M) |
| Sells | 30 ($207.96M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Lilly Endowment, Inc: 10.1% (-0.5%)
- Vanguard Group Inc: 8.6% (+0.7%)
- Blackrock Inc.: 7.0% (-0.2%)
- PNC Financial Servic: 5.4% (+0.1%)
- State Street Corpora: 3.7% (+0.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-2.0% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $208M sold (30 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 9 raises (avg +16%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.

### Fundamentals

PEG ratio 0.90 indicates undervaluation relative to growth. Forward P/E 31.0x attractive for 36% earnings growth. Quality metrics strong (ROE 96%, ROA 18%, margin 31%). Balance sheet: $8.6B free cash flow. Analyst sentiment positive (9 raises, avg +16%). Insider selling cluster ($208.0M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $894.3B |
| Beta | 0.37 |
| 52W Range | $623.78 - $1111.99 |
| Short Interest | 0.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.90 |
| Forward P/E | 31.0 |
| Current P/E | 42.1 |
| YoY Growth | 35.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -4.1% to -6.1% (-2.0% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 9.1pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.23x) but short-term weakness (below SMA20). MACD histogram bearish (-15.12), momentum weakening. RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -6.09% (CS: 3) | Weak |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | -15.12 | Bearish |
| vs SMA20 | 0.962x | Below |
| vs SMA50 | 1.088x | Above |
| vs SMA200 | 1.228x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $997.59
- **Stop Loss:** $941.45 (5.6% risk)
- **Target:** $1053.73 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 8
- **Position Value:** $7,980.72
- **Portfolio %:** 7.98%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-05 (Est: $7.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.89 | $7.02 | +19.1% |
| 2025Q2 | $5.59 | $6.31 | +12.9% |
| 2025Q1 | $3.54 | $3.34 | -5.7% |
| 2024Q4 | $5.07 | $5.32 | +5.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*